Harnessing the power of cytokines to restore immune function

OUR FOCUS

Brooklyn ImmunoTherapeutics is focused on exploring the role that the human immune system can have in treating patients with cancer and immunologic diseases, both as a single agent and in combination with other therapies.

Our most advanced program is studying the safety and efficacy of IRX-2, a human cell-derived (hd) IL-2 therapeutic in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 was well-tolerated and demonstrated an overall survival benefit. Additional single agent and combination studies are either underway or planned in other solid tumor cancer indications.

LATEST NEWS

Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial

[ READ MORE ]

2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

[ READ MORE ]

Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

[ READ MORE ]